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http://dx.doi.org/10.1016/j.pedneo.2
1875-9572/Copyright ª 2015, Taiwan P
NC-ND license (http://creativecommoBackground: The aim of this study was to investigate the treatment response of entecavir
(ETV) in children and adolescents with chronic hepatitis B (CHB) who acquired infection peri-
natally or during early childhood.
Methods: A total of nine treatment-naı¨ve patients [median aged 12.2 years (range: 2.6e18.0);
five girls and four boys], with hepatitis B e antigen (HBeAg) seropositive > 6 months, alanine
aminotransferase (ALT) > 2 times of upper limit of normal value (30 IU/L), were enrolled for
ETV therapy. They received ETV therapy with a dose of 0.015 mg/kg/d, with a maximal dose of
0.5 mg daily for at least 52 weeks. Another 27 untreated CHB patients matched for age, sex,
ALT levels, and HBeAg status were recruited as the control group. A complete response at 48
e52 weeks was defined as follows: (1) normalization of ALT; (2) undetectable hepatitis B virus
DNA; and (3) HBeAg/anti-HBe seroconversion. All 36 patients were retrospectively reviewed
for their biochemical, serological, and virologic responses.
Results: ETV-treated patients achieved rapid ALT normalization (all before 8 months of treat-
ment) compared with the control group (p < 0.001) and they had a greater chance of
achieving undetectable HBV DNA levels at Week 52 after treatment (55.6% vs. 11.1%,
p Z 0.013). The cumulative incidence rates of HBeAg seroconversion were similarly high in
both groups (ETV group 44% at 1 year 78% at 2 years; control group 37% at 1 year 63% at 2 years,
respectively). The ETV group also had a trend of better complete response than the control
group (22.2% vs. 0%, pZ 0.057). None of the ETV-treated patients reported significant adverse
effects.t of Pediatrics, National Taiwan University Hospital, Number 8, Chung-Shan South Road, Taipei,
.tw (M.-H. Chang).
015.09.009
ediatric Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-
ns.org/licenses/by-nc-nd/4.0/).
Entecavir treatment in children and adolescents 391Conclusion: Entecavir for pediatric CHB treatment is safe and shows clinical benefits in short-
term biochemical and virologic responses. Further studies to determine long-term remission
and drug resistance are required.
Copyright ª 2015, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/).1. Introduction
Chronic hepatitis B virus (HBV) infection remains a health
burden in both children and adults, especially in countries
where HBV infection is highly endemic. Although universal
HBV immunization has been well established for over
28 years in Taiwan, HBV infection still is not eradicated
completely in vaccinated birth cohorts.1e3 In spite of
complete immunization with HBV vaccines and hepatitis B
immunoglobulin, around 10% of infants acquired HBV
infection perinatally through hepatitis B e antigen (HBeAg)-
positive HBV carrier mothers.2e4 Infection acquired at a
young age and prolonged inflammation over decades pre-
dispose the children to the hazard of chronic liver injury,
liver cirrhosis, and hepatocellular carcinoma (HCC) over
their lifetimes.5e7 For those who have been infected,
treatment for children or young adults remains a great
issue. In addition, strategies such as who may benefit from
the intervention, what is the most appropriate timing for
treatment, and the choice of antiviral agents are still
unsolved.8e10
Although many kinds of effective and safe anti-HBV
therapies are available in adults, few drugs are licensed to
be used in the limited age range of the pediatric group.
Currently, conventional interferon-alpha (IFN-ɑ) can be
used in children older than 1 year of age, lamivudine (LAM)
in children older than 3 years of age, adefovir and tenofovir
starting at 12 years of age, and entecavir (ETV) for children
more than 2 years of age.10e12
Treatment for children with chronic hepatitis B (CHB)
was initiated with IFN-ɑ and LAM historically. In our previ-
ous experience of IFN-ɑ, there was no significant difference
in the rate of HBeAg seroconversion and HBV DNA sup-
pression to < 105 copies/mL between IFN-ɑ treated and
untreated control patients at 1 year and at 6 years after
stopping treatment.13 IFN-ɑ also has several adverse effects
such as flu-like symptoms, neutropenia, and behavioral
disorders. Our previous study of LAM showed no difference
in the rate of HBeAg seroconversion (38% vs. 34%) and
reduction in HBV DNA to less than 102 copies/mL (17% vs.
10%) at 1 year, as compared with untreated control pa-
tients.14 Tyrosine-methionine-aspartate-aspartate mutants
developed in 34% of this LAM-treated group, which was
consistent with another study showing that LAM was asso-
ciated with a high rate of drug resistance under long-term
use.14 Adefovir therapy showed no difference between
treated patients and placebo control in children aged
2 years to < 12 years, with a lower risk of antiviral drug
resistance than LAM.15 ETV is superior to LAM in adult pa-
tients in terms of HBV viral suppression and much less HBV
resistance strain development. These observationsprompted us to consider ETV as the primary treatment
choice of our CHB children from 2008 onwards.2. Methods2.1. Patients
We performed a retrospective, matched case-control study
(1:3 ratio) consisting of ETV-treated and treatment-naı¨ve
CHB patients. We recruited pediatric CHB patients who
started to receive ETV therapy in the Department of Pedi-
atrics, National Taiwan University Hospital consecutively
between January 2008 and July 2014. These children or
adolescents with CHB had received long-term follow up in
our outpatient clinics regularly since they were identified
to be HBsAg-positive at initial screening. Most of them were
identified to have acquired HBV infection perinatally or
during early childhood. Patients were eligible for inclusion
if they were younger than 19 years at the initiation of
treatment and met the following criteria: (1) both HBsAg
and HBeAg seropositive for > 6 months; and (2) elevation of
alanine aminotransferase (ALT) levels > 2 times of upper
limit of normal value (ULN; 30 IU/L) for at least two mea-
surements over more than 6 months.16
Patients were excluded if they had concomitant infec-
tion with hepatitis C virus, hepatitis D virus, human im-
munodeficiency virus, decompensated liver disease or
other severe systemic disease, or if they had positive serum
anti-HBe at enrollment. In addition, patients could not have
received IFN therapy or other antiviral agents before. A
liver biopsy performed within 12 months before treatment
was recommended but was not absolutely indicated.
In CHB children with elevated ALT serum levels (>2 ULN)
for longer than 6 months, clinicians carefully explained the
advantages and disadvantages of the current antiviral drugs
available in the pediatric group to the parents and children,
including the route of administration, adverse effects, and
resistance rate. After deliberation, they finally gave con-
sent to use ETV as their anti-HBV therapy with off-label use.
In total, nine patients who had received ETV therapy ful-
filled the study criteria and were enrolled in our ETV
treatment group. The expenses of antiviral treatment were
paid by health insurance coverage.
For comparison, three control participants were
selected for each patient. Control participants consisted
of treatment-naı¨ve CHB patients who underwent regular,
long-term follow-up at our department. Each control group
patient who was matched for sex, age, HBeAg status, and
ALT level with his/her corresponding treated patient
(Table 1).
Table 1 Baseline characteristics of the entecavir-treated
group and control group.
Entecavir
(n Z 9)
Control
(n Z 27)
p
Sex
Male 4 12 1
Female 5 15
Age (yr), median (range) 12.1
(2.6e18.0)
13.3
(1.0e18.4)
0.87
<6 yrs 2 6 1
6 yr to < 13 yr 3 11
13 yr 4 10
ALT level (U/L),
median (range)
356
(136e1086)
349
(102e1254)
0.62
2 to < 5 times of UNL 3 9 1
5 times of UNL 6 18
HBV DNA level
(log10 copies/mL),
median (range)
8.0
(6.97e8.83)
7.7
(3.12e10.0)
0.53
108 copies/mL 6 12 0.44
<108 copies/mL 3 15
Genotype
B 6 17 1
C 3 10
ALT Z alanine aminotransferase; HBV Z hepatitis B virus.
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current study was conducted as an expedited review in
accordance with the ethics principles of the Declaration of
Helsinki guidelines. The study protocol was approved by the
Ethics Committee of National Taiwan University Hospital’s
Institutional Review Board (IRB number: 201312031RIND).
2.2. Treatment and follow-up of patients
The patients in the treatment group received ETV therapy
with a dose of 0.015 mg/kg/d, and a maximal dose of 0.5mg
daily. According to the HBV antiviral protocol “Hepatitis B
or C Health Care Program” of our Bureau of National Health
Insurance, the treatment duration was expected to be at
least 1 year but no longer than 3 years, aiming for HBeAg
loss and anti-HBe seroconversion. If patients achieve HBeAg
seroconversion successfully, they are suggested to use
antiviral drugs for at least 1 more year from the time point
of seroconversion by the protocol. The importance of
compliance was emphasized before therapy and the
adherence to drug was assessed at every visit. Informed
consent was obtained for each patient who received ETV
therapy.
All treated and untreated patients were followed-up
regularly at out-patient clinics. Detailed history and phys-
ical examinations were evaluated. Serum ALT level, HBV
serology including HBsAg, HBeAg, and anti-HBe was
checked periodically at baseline, every 1e2 months in the
first 6 months after entry, followed by every 3e6 months in
the subsequent period. A commercially available enzyme
immunoassay (Abbott Molecular, IL, USA) was used to
determine these HBV markers. In addition, serum HBV DNA
was quantified within 1 month before study entry and atWeek 52 after treatment with the aid of a sensitive real-
time polymerase chain reaction assay (Abbott Molecular, IL,
USA; and Roche Molecular Systems). The detection limit of
the method was 70 copies/mL.
We retrospectively compared their physical, biochem-
ical, and virologic responses. We also reviewed carefully to
assess if any adverse effects were mentioned on the chart
records. Hepatitis flares during treatment were defined as
re-elevation of ALT levels to more than two times of the ULN
after ALT normalization has been achieved successfully.
2.3. Definitions
For the treatment group, a complete virologic response in
this study was defined as suppression of HBV DNA to an
undetectable level assessed using real-time polymerase
chain reaction (<70 copies/mL). Furthermore, a complete
response at 48e52 weeks was defined as follows: (1)
normalization of ALT; (2) undetectable hepatitis B virus
DNA; and (3) HBeAg/anti-HBe seroconversion (loss of HBeAg
and emergence of anti-HBe on at least two consecutive
follow-ups).
2.4. Statistical tests
The results are expressed as median and range. Dichoto-
mous variables were calculated using Chi-square test with
Yates’s correction or Fisher’s exact test. Continuous vari-
ables were analyzed using ManneWhitney U test. We used
KaplaneMeier method to assess the time of the ALT
normalization and HBeAg seroconversion using log-rank test
to compare the cumulative incidences between ETV and
control groups. Statistical analysis was considered as sig-
nificant if a p value < 0.05, and as trend if a p value
0.05e0.1.
3. Results
3.1. Baseline features in treated and control
patients
Among the nine ETV-treated and 27 control patients, there
were no significant differences between the treatment
group and the control group regarding the age, sex, initial
ALT level, or serum HBV DNA concentration at entry, with
their baseline demographics illustrated in Table 1. In the
ETV-treated group, there were six cases of genotype B and
three cases of genotype C. Similarly, the majority in the
control group were genotype B, presenting with 17 among
27 cases. There was no difference in the genotype distri-
bution among ETV-treated and control groups (Table 1).
All cases in the treatment group and 21 of the 27 cases in
control group were born to HBsAg-positive mothers, so the
major source of HBV infections may be attributable to
mother-to-infant transmission.
3.2. Clinical follow-up
All the nine patients in the treatment group received ETV
therapy for more than 1 year, five patients for more than
Figure 1 KaplaneMeier method estimations of cumulative
rates of alanine transaminase normalization and hepatitis B e
antigen (HBeAg)/anti-HBe seroconversion, comparing a ente-
cavir (ETV)-treated group and a control group: (A) cumulative
proportion (%) of alanine transaminase normalization rate at
3 years after entry was statistically higher in the ETV-treated
group than control patients (p < 0.001, log-rank test); and
(B) cumulative proportion (%) of HBeAg to anti-HBe serocon-
version in ETV-treated group was not significantly different to
the control group (p Z 0.48). ALT Z alanine transaminase;
ETV Z entecavir; HBeAg Z hepatitis B e antigen.
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(11.1%). Seven patients achieved HBeAg/anti-HBe sero-
conversion within 1 year after therapy, and they received
an additional year of ETV treatment from the time point of
seroconversion and then stopped ETV, according to the
protocol mentioned above. The other two ETV-treated pa-
tients had taken medicine for 2.9 years and 1.5 years
respectively, and they were still under ETV therapy due to
persistently positive HBeAg. All of the 27 control patients
were followed up for more than 3 years. No patient in the
treated or control group developed liver decompensation or
hepatocellular carcinoma during the follow-up period.
3.3. Assessment of treatment efficacy
By KaplaneMeier analysis, the cumulative incidence of ALT
normalization within the 3-year observation was signifi-
cantly higher in the ETV-treated group than in the control
group (p < 0.001). All ETV-treated patients had ALT
decreasing to below ULN within 1 year, with a median
duration of 3.5 months (range, 1.1e7.4 months). In
contrast, only 14 of the 27 patients in the control group
achieved ALT normalization within one year (median,
6.1 months, range, 1.8e11.9 months; p Z 0.014 for the
comparison with ETV group). However, the cumulative rate
of HBeAg to anti-HBe seroconversion did not differ between
the ETV-treated group and the control group (p Z 0.48;
Figure 1). In addition, HBsAg clearance was neither detec-
ted in the ETV-treated group nor observed in the control
group.
All nine ETV-treated patients and 27 patients in the
control group received HBV DNA measurements at pre-
treatment and at 1 year after study entry. The proportion
of 2 log10 reduction of serum HBV DNA from baseline to
Week 52 showed a trend of higher rate in the ETV-treated
group, compared with the control group (88.9% vs. 51.8%,
p Z 0.062). In addition, five (55.6%) of nine ETV-treated
patients had complete viral response with decreasing HBV
DNA to undetectable levels at 1 year after study entry,
which was significantly higher than that of the control
group (three of 27, 11.1%, p Z 0.013; Table 2).
Two patients of the ETV-treated group achieved com-
plete response with ALT normalization, HBeAg seroconver-
sion, and undetectable HBV DNA at 1 year after treatment,
but no patient in the control group met these criteria under
a natural course (p Z 0.057; Table 2). Two of six (33.3%)
patients with genotype B and one of three (33.3%) patients
with genotype C in the ETV-treated group achieved HBeAg
seroconversion at 1 year after treatment. Seven of seven-
teen (41.2%) patients with genotype B and three of ten
(30.0%) patients with genotype C in control group attained
the similar aim at one year since study entry. Compared
with the control group, neither genotype B nor genotype C
patients in ETV-treated group had higher rates of HBeAg
seroconversion.
3.4. Adverse effects
No obvious adverse effects were reported by ETV-treated
patients and/or by their caretakers during the treatment
according to the chart records. All ETV-treated patientsseemed to tolerate it well and none ceased therapy before
completing the treatment course. A 10-year-old boy in the
ETV-treated group had a transient mild hepatitis flare
during treatment. His ALT level at pretreatment was 356 U/
L initially and this decreased to 21 U/L successfully under
ETV therapy for 6.4 months and normalization of ALT per-
sisted for longer than 6 months. ALT level rebound up to
87 U/L was observed at 15.3 months after treatment, but it
readily dropped to below ULN 1 month later. HBeAg loss
with anti-HBe emergence was found at the same time, and
Table 2 Biochemical, serologic, and virologic responses
at 1 year after study entry.
52 wk after study entry Entecavir
(n Z 9)
Control
(n Z 27)
p
HBV DNA reduction > 2 log10
copies/mL
88.9%
(8/9)
51.8%
(14/27)
0.062
HBV DNA < 70 copies/mL 55.6%
(5/9)
11.1%
(3/27)
0.013
ALT normalization 100%
(9/9)
51.9%
(14/27)
0.009
HBeAg seroconversion 44.4%
(4/9)
37.0%
(10/27)
0.693
ALT normalization, HBeAg
seroconversion, and HBV
DNA < 70 copies/mL
22.2%
(2/9)
0%
(0/27)
0.057
ALT Z alanine aminotransferase; HBeAg Z hepatitis B e anti-
gen; HBV Z hepatitis B virus.
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in total.4. Discussion
Treatment guidelines of children and adolescents with
chronic HBV infection are still evolving, and most of them
were based on consensus of expert opinions.8e10 Although
most children or adolescents with chronic HBV infection
remain asymptomatic for decades, they have the potential
risk over a long lifespan to develop severe liver disease
including liver cirrhosis or HCC. High HBV DNA level, a
marker of active viral replication for children and adoles-
cents in immune tolerance phase, is the driving force to
induce acute hepatitis. Persistent ALTelevation can result in
remarkable hepatic damage and increase the risks of HBV-
related liver cirrhosis and HCC.17 Timely intervention with
anti-HBV therapy can benefit these patients by halting and
reversing the premalignant tendency.18 Therefore, if chil-
dren or adolescents have comparable responses to treat-
ment as adults, it may be cost-effective and desirable to
treat HBV infection as early as possible, since complications
can occur at any time during childhood or adult life.19
Our data suggested that ETV had a good efficacy in the
treatment group as compared with control groupwith regard
to treatment response. Since its therapeutic experiences for
CHB children or adolescents were still scarce, these data
may provide some important reference information. In one
clinical trial reported previously, 55 of 82 (67%) ETV-treated
patients aged 2 years to < 18 years achieved ALT normali-
zation after 48 weeks of treatment.12 Our study showed that
ALT values in all patients of the ETV-treated group normal-
ized within 1 year after treatment. In addition, the speed of
ALT decrement to normal range was remarkably faster than
in the untreated control group. ETV seemed to serve as a
potent agent to reduce liver inflammation promptly, and this
may possibly lead to a further beneficial effect to prevent
hepatic fibrosis in children and adolescents.20
Furthermore, the rate of complete virologic response at
1 year after ETV treatment for children and adolescents
was higher than those without treatment. The treatedcases with reduction of serum HBV DNA to undetectable
levels accounted for 55.6% in this study. Since large cohort
studies in adult groups had demonstrated a clear associa-
tion between high levels of HBV DNA and subsequent pro-
gression to cirrhosis, HCC, and death over a 10-year
period,17,21,22 successfully restrained HBV DNA replication
under ETV treatment may hopefully help CHB children or
adolescents to reduce the risk of disease complications.
Sustained HBV virologic suppression is the major goal of
treatment.23 Further long-term follow up is needed to
evaluate its effect on this goal.
Pawlowska et al24 showed that 23% of 22 previously
treated HBeAg-positive children achieved HBV DNA disap-
pearance after ETV treatment for 24 weeks. With regard to
ETV 1-year treatment efficacy, previous studies in adult
groups reported by Iloeje et al21 and Chang et al25
demonstrated HBV DNA repression to undetectable values
in 52.1% and 67% of HBeAg-positive patients, respectively.
One clinical trial in pediatric patients also revealed that
58% of treatment-naı¨ve patients achieved HBV DNA
depression to < 50 IU/mL after ETV treatment for
48 weeks.12 Although our presented rate of 55.6% was not
greatly higher than the rates reported in previous studies,
this report still disclosed that ETV was a potent anti-HBV
agent for children and adolescents.
According to treatment experiences in adult group, the
severe adverse effects reported under ETV treatment may
occur in as many as 9e10% of adult populations.25e27 Based
on two ongoing clinical trials in pediatric patients who
received ETV treatment, the adverse reactions were
consistent with those observed in adults, in which abdominal
pain, rash events, poor palatability, nausea, and diarrhea
may be reported [one phase 2 pharmacokinetic trial
(AI463028) and one phase 3 trial (AI463189)].12 Fortunately,
none of our nine ETV-treated patients in our study experi-
enced any discomfort, and all of them tolerated the therapy
fairly well. Although one case presented with mild hepatitis
flare during ETV treatment, he did not have any symptoms
such as headache, malaise, fever, or jaundice. Spontane-
ously declining ALT level was noted at the next blood sam-
pling, accompanied with HBeAg seroconversion. No virologic
breakthrough was detected in the serial lab examinations,
and emergence of drug resistance was not considered. Our
tolerability profile of ETV may provide important informa-
tion that it was well tolerated by children and adolescents
with CHB. However, long-term safety should be confirmed by
continued and persistent surveillance.
Our current study was limited in its small sample size
and retrospective nature, and there is a need to collect
more eligible patients. Multicentered clinical trials with
ETV therapy in children < 18 years are ongoing and long-
term follow-up studies are needed.28,29
In conclusion, the current study showed that ETV
treatment had beneficial effects on ALT normalization and
substantial viral suppression in pediatric CHB patients. It
may serve as an effective alternative antiviral agent in the
treatment of CHB in children and adolescents.Conflicts of interest
All authors declare no conflicts of interest.
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